Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 4/20 | 0.55 |
| ▸ | JAK1 | P23458 | 2/20 | 0.55 |
| ▸ | TYK2 | P29597 | 2/20 | 0.55 |
| ▸ | JAK3 | P52333 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632738 | 0.88 | JAK2 (0.59) | MAPK10JAK2JAK1TYK2JAK3 | |
| SCHEMBL1633401 | 0.87 | HRH3 (0.51) | MAPK10JAK2HRH3LRRK2 | |
| SCHEMBL1632375 | 0.87 | LRRK2 (0.51) | MAPK10JAK2HRH3LRRK2 | |
| SCHEMBL1632073 | 0.87 | CDK4 (0.57) | MAPK10JAK2JAK1TYK2JAK3 | |
| SCHEMBL1632408 | 0.86 | JAK2 (0.56) | JAK2JAK1TYK2JAK3HRH3 | |
| SCHEMBL1633525 | 0.86 | JAK2 (0.56) | JAK2JAK1TYK2JAK3HRH3 | |
| SCHEMBL1633858 | 0.85 | JAK2 (0.49) | MAPK10JAK2JAK1TYK2JAK3 | |
| SCHEMBL1632641 | 0.84 | JAK2 (0.60) | JAK2JAK1TYK2JAK3HRH3 | |
| SCHEMBL12724803 | 0.84 | JAK1 (0.57) | MAPK10JAK2JAK1TYK2JAK3 | |
| SCHEMBL1631106 | 0.83 | JAK2 (0.57) | JAK2JAK1TYK2JAK3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | MAPK10 402/4885JAK2 1352/4885JAK1 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.